Research ArticleClinical Investigations
Radioimmunoscintigraphy and Pretreatment Dosimetry of 131I-Omburtamab for Planning Treatment of Leptomeningeal Disease
Neeta Pandit-Taskar, Milan Grkovski, Pat B. Zanzonico, Keith S. Pentlow, Shakeel Modak, Kim Kramer and John L. Humm
Journal of Nuclear Medicine June 2023, 64 (6) 946-950; DOI: https://doi.org/10.2967/jnumed.122.265131
Neeta Pandit-Taskar
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;
2Department of Radiology, Weill Cornell Medical College, New York, New York;
Milan Grkovski
3Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York; and
Pat B. Zanzonico
3Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York; and
Keith S. Pentlow
3Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York; and
Shakeel Modak
4Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
Kim Kramer
4Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
John L. Humm
3Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York; and
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 64, Issue 6
June 1, 2023
Radioimmunoscintigraphy and Pretreatment Dosimetry of 131I-Omburtamab for Planning Treatment of Leptomeningeal Disease
Neeta Pandit-Taskar, Milan Grkovski, Pat B. Zanzonico, Keith S. Pentlow, Shakeel Modak, Kim Kramer, John L. Humm
Journal of Nuclear Medicine Jun 2023, 64 (6) 946-950; DOI: 10.2967/jnumed.122.265131
Radioimmunoscintigraphy and Pretreatment Dosimetry of 131I-Omburtamab for Planning Treatment of Leptomeningeal Disease
Neeta Pandit-Taskar, Milan Grkovski, Pat B. Zanzonico, Keith S. Pentlow, Shakeel Modak, Kim Kramer, John L. Humm
Journal of Nuclear Medicine Jun 2023, 64 (6) 946-950; DOI: 10.2967/jnumed.122.265131